Physician profile
Brandon William Mcnally
NPI 1073740833
$7,982.87
in general payments reported to CMS, 2019-2025
34 companies · $2,229 in 2025
The $2,229 reported for 2025 was more than what 87% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $164 · 2021: $366 · 2022: $612 · 2023: $2,360 · 2024: $2,253 · 2025: $2,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,481 · Education: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,481.28 |
| Education | $360.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,424.20 | 2020-2025 | |
| Janssen Biotech, INC. | $1,068.05 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $1,029.67 | 2020-2025 | |
| Genzyme Corporation | $662.50 | 2020-2025 | |
| Dermavant Sciences, INC. | $441.94 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $399.28 | 2020-2025 | Dupixent |
| Pfizer INC. | $336.99 | 2022-2025 | |
| Incyte Corporation | $321.77 | 2023-2025 | Opzelura |
| Amgen INC. | $281.39 | 2022-2025 | Otezla, Otezla, Enbrel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.36 | 2023-2025 | Spevigo, Cyltezo |
| Sun Pharmaceutical Industries INC. | $217.48 | 2020-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $213.03 | 2023-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $202.72 | 2023-2025 | Zoryve |
| Organon LLC | $191.88 | 2023-2025 | Hadlima, Vtama |
| Ucb, INC. | $173.05 | 2023-2025 | Bimzelx, Cimzia |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $151.32 | 2020-2025 | Ebglyss, Taltz, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $71.61 | 2022-2025 | Siliq, Targretin |
| Fresenius Kabi USA, LLC | $64.56 | 2023-2024 | Idacio |
| Biofrontera INC. | $58.51 | 2021-2022 | |
| Galderma Laboratories, L.P. | $56.75 | 2025 | Nemluvio |
| Almirall LLC | $53.32 | 2021-2022 | |
| Kyowa Kirin, INC. | $39.30 | 2023 | Poteligeo |
| Genentech USA, INC. | $34.45 | 2022-2023 | Xolair |
| Lnhc, INC | $29.06 | 2025 | Zelsuvmi |
| Blueprint Medicines Corporation | $27.57 | 2023 | |
| Vyne Pharmaceuticals INC. | $24.71 | 2020 | |
| Krystal Biotech INC | $20.73 | 2025 | Vyjuvek |
| Mylan Institutional INC. | $20.38 | 2023 | |
| Sanofi-Aventis U.S. LLC | $18.79 | 2021 | |
| Biocon Biologics INC | $17.29 | 2024 | Hulio |
| Organogenesis INC. | $17.18 | 2024 | |
| Leo Pharma INC. | $14.05 | 2023 | Adbry |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Mayne Pharma Commercial LLC | $7.81 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Mcnally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.